-
Focusing on the FundamentalsNational Cancer Institute director Norman “Ned” Sharpless meets with advocates and outlines areas of focus for the agency.
by Marci A. Landsmann
-
Supporting SurvivorsPanel of experts discuss survivorship challenges and potential areas for study.
by Marci A. Landsmann
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Artificial Intelligence Characterizes CancerAt the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
by Kevin McLaughlin
-
Cancer Researchers Offer Reasons for OptimismCancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.
by Kevin McLaughlin
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
The Evolving Role of Patient AdvocacyAACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.
by Marci A. Landsmann
-
An Advocate’s Guide to Attending Scientific MeetingsTwo graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.
by Bob Riter and Carole Baas
-
Making Decisions About Breast SurgeryPatients who opt for breast reconstruction after mastectomy tend to overestimate how happy they will be with the results, while those who do not get reconstruction tend to underestimate their future satisfaction.
by Cici Zhang
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore
-
Inaugural AACR IO Conference Kicks Off With Celebration of Immune CheckpointsImmune checkpoint icons James Allison and Arlene Sharpe shared their journeys and a look ahead on the opening night of the inaugural AACR IO conference.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
